Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02886637

Enrollment

Registered

2016-09-01

Start date

2015-07-31

Completion date

2016-03-31

Last updated

2016-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acinetobacter Baumannii Infection

Keywords

A baumannii infection, Immunosuppression, prognosis, immune function

Brief summary

The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.

Detailed description

This is a single-center, observational study. Patients with Acinetobacter baumannii infection in the intensive care unit of Zhongda Hospital were enrolled. We recorded the data of age, ICU admission diagnosis, underlying diseases, APACHE II score and infection site. Body temperature, heart rate, white blood cell counts, procalcitonin, C-reactive protein, SOFA score and the level of CD4+, CD8+, Th1, Th2 and HLA-DR in the blood measured by flow cytometry on the D1, D3 and D7 were also recorded.We can get the results of the change of immune function of critical ill patients after Acinetobacter baumannii infection. After compare the patients who die of survive at 28 day after infection, we can get the results of the relationship between the immune function and the outcome. We also can calculate the effect immune function on prognositic mortality in patients with Acinetobacter baumannii infection.

Interventions

OTHERNone intervention

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients admitted to ICU * Infection with Acinetobacter baumannii * Agree to participate the study

Exclusion criteria

* Age less than 16 years old or older than 80 years old * pregnancy * immunosuppression patients which include 1. therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month 2. Cancer chemotherapy within recent 3 month 3. Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases 4. allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation. 5. HIV infection

Design outcomes

Primary

Measure	Time frame
28 day mortality	28 day

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026